Alkermes Plc Hits New 52-Week High of $53.67, Up 118.4%

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 53.67 on June 25, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 5,008 million. Over the past year, Alkermes has demonstrated impressive growth, with a remarkable 118.4% increase in its stock price, significantly outperforming the S&P 500, which recorded a gain of 20.77% during the same period. The company's price-to-earnings (P/E) ratio stands at 21.00, indicating a solid valuation relative to its earnings. Alkermes maintains a return on equity of 13.28%, reflecting its ability to generate profit from shareholders' equity. Additionally, the company's price-to-book ratio is 2.75, suggesting a healthy valuation compared to its net assets. With no dividend yield and a debt-to-equity ratio of -0.72, Alkermes appears to be managing its financial structure effectively. The stock's previous 52-week low was recorded at USD 25.17, highlighting the significant upward trajectory it has experienced.